FDA
-
-
-
-
-
-
-
Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
-
-
-
-
-
-
-
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties
-
-
-
-
-
-
-
Kiadis Pharma to lease existing commercial manufacturing facility in The Netherlands
-
-
-
-
-
328,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

